Impact of Phenylketonuria-type Diet on Appetite, Appetite Hormones and Diet Induced Thermogenesis
1 other identifier
interventional
26
1 country
1
Brief Summary
Low-phenylalanine diets are commonly prescribed to people with phenylketonuria (PKU), an inborn disease which causes accumulation of amino acid phenylalanine (Phe) in the blood. High blood Phe levels can cause mental, behavioural, neurological, and physical problems. Thus, low-phenylalanine diets help patients to manage their condition but it is not clear whether they have an impact on appetite, energy intake and changes in body weight. This is important to explore as prevalence of obesity in this population is rising high. This study aims to find out the effect of PKU-type meals on appetite, appetite biomarkers, and post-meal energy expenditure. The investigators will recruit 26 healthy adults and ask them to participate in two experimental trials. On one occasion the participants will be asked to consume a PKU-supplemented drink followed by a PKU type-lunch and on another occasion the supplement and lunch will be based on normally consumed foods. Series of blood samples will be taken and appetite will be assessed during both experiments. Both experimental trials will finish with consuming an "all-you-can-eat" buffet.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Nov 2014
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2014
CompletedFirst Submitted
Initial submission to the registry
April 30, 2015
CompletedFirst Posted
Study publicly available on registry
May 12, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2016
CompletedMay 23, 2016
May 1, 2016
1.3 years
April 30, 2015
May 20, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (7)
Appetite hormone: peptide YY (PYY)
Plasma concentration at baseline (0 minute) and after ingestion of supplement (at 30, 60 and 90 minutes) and lunch (at 120, 150,180, 210, 240, 270 and 300 minutes)
300 minutes
Appetite hormone: glucagon-like peptide-1 (GLP-1)
Plasma concentration at baseline (0 minute) and after ingestion of supplement (at 30, 60 and 90 minutes) and lunch (at 120, 150,180, 210, 240, 270 and 300 minutes)
300 minutes
Appetite hormone: cholecystokinin (CCK)
Plasma concentration at baseline (0 minute) and after ingestion of supplement (at 30, 60 and 90 minutes) and lunch (at 120, 150,180, 210, 240, 270 and 300 minutes)
300 minutes
Appetite hormone: insulin
Plasma concentration at baseline (0 minute) and after ingestion of supplement (at 30, 60 and 90 minutes) and lunch (at 120, 150,180, 210, 240, 270 and 300 minutes)
300 minutes
Appetite hormone: ghrelin
Plasma concentration at baseline (0 minute) and after ingestion of supplement (at 30, 60 and 90 minutes) and lunch (at 120, 150,180, 210, 240, 270 and 300 minutes)
300 minutes
Subjective appetite score
Visual analogue scale (VAS) collected at baseline and after each blood sample collection
300 minutes
Diet induced thermogenesis
Metabolic rate by means of computerised open-circuit ventilated hood system collected at baseline and after each blood sample collection for the duration of 20 minutes
300 minutes
Secondary Outcomes (2)
Taste perception of PKU supplements/foods
10 minutes
Consumption time for PKU supplements/foods
20 minutes
Study Arms (2)
Phenylketonuria-type diet
EXPERIMENTALBreakfast: one pouch of amino acid supplement (174 mls supplemented drink PKU cooler 20, Vitaflo®; 20 g protein, 9.4 g carbohydrates, 0.7 g Fat) Lunch: cheese sandwich \[low protein bread (Juvela, UK), no protein vegan cheese (Viotros, UK)\], low protein crackers (Vitaflo, UK), and low protein cookies (Juvela, UK). Dinner: ad libitum buffet meal
Normal diet
OTHERBreakfast: 174 ml of milk (20 g protein, 9.4 g carbohydrates, 0.7 g Fat) Lunch: cheese sandwich, crackers, and cookies (regular foods) Dinner: ad libitum buffet meal
Interventions
Breakfast, lunch and open buffet dinner
Breakfast, lunch and open buffet dinner
Eligibility Criteria
You may qualify if:
- Healthy adult
- Body weight stable for previous 4 months
- Regular menstrual cycle (females)
You may not qualify if:
- Pregnancy or lactation (females)
- History of eating disorder
- History of gastrointestinal problems or surgery
- History of allergy
- History of chronic illness
- On any medication
- Smoking
- On nutritional supplements
- Following specific diet
- Currently taking part in other research
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Human Nutrition, School of Medicine, University of Glasgow
Glasgow, G31 2ER, United Kingdom
Related Publications (1)
Alfheeaid H, Gerasimidis K, Nastase AM, Elhauge M, Cochrane B, Malkova D. Impact of phenylketonuria type meal on appetite, thermic effect of feeding and postprandial fat oxidation. Clin Nutr. 2018 Jun;37(3):851-857. doi: 10.1016/j.clnu.2017.03.005. Epub 2017 Mar 8.
PMID: 28318688DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Dalia Malkova, PhD
University of Glasgow
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Senior Lecturer
Study Record Dates
First Submitted
April 30, 2015
First Posted
May 12, 2015
Study Start
November 1, 2014
Primary Completion
March 1, 2016
Study Completion
March 1, 2016
Last Updated
May 23, 2016
Record last verified: 2016-05